Treatment of schizophrenia, the first pure "domestic medicine" came

in schizophrenia patients on the long prescription list, "purely domestic" absent, "foreign technology" has become the main character. Now, the good news is coming.
In mid-January, china's first independent research and development, globally registered, innovative micro-ball preparation with independent intellectual property rights was approved for listing by the State Drug Administration, which broke the foreign technology monopoly. Science and Technology Daily learned from the team that the new results are used to treat acute and chronic schizophrenia and other psychiatric conditions of the obvious positive symptoms and obvious negative symptoms, can reduce the emotional symptoms associated with schizophrenia.
, high-end complex preparations such as lipids, microspheres, etc., often have obvious clinical advantages, with better effectiveness and safety. At the same time, injection micro-ball preparation is a complex preparation, its research and development, production difficulties, high technical barriers, before mainly by several foreign enterprises. The National Development and Reform Commission, the Ministry of Science and Technology and other six ministries in 2016 jointly issued the "Pharmaceutical Industry Development Planning Guide", clearly put forward to focus on the development of micro-balls, including high-end preparations, the development of high-end preparations industrialization technology.
Based on Yantai University and Green leaf pharmaceutical group "production, research and development" cooperation integrated platform, Yantai University pharmaceutical teachers as the core backbone of the research and development team after years of efforts, one after another to break through the technical barriers of new high-end preparations, to create the world's leading new long-acting preparation technology platform, around the needs of patients, in the field of cancer, central nerve and other major diseases in-depth layout. The new research and development, called Rui Xinto, was jointly conducted by Yantai University Professor Sun Kaoxiang in Green Leaf Pharmaceuticals, with Liu Wanhui and Professor Tian Jingwei as key members.
Singtai University School of Pharmacy
Wang Hongbo stressed to science and technology daily reporters that the results of the project led by Yantai University, with the Green Leaf Pharmaceutical Group,
Shanghai Pharmaceutical Institute, China Medical
Pharmaceutical Institute, China Pharmaceutical University and other six units, is its construction of the "new preparations and biotechnology drug research and innovation center" collaborative innovation results.
schizophrenia is a chronic and serious mental disorder that affects more than 20 million people worldwide. Due to the low compliance of patients with treatment, the recurrence rate is high, and the disease has repeatedly become one of its major difficulties.
team experts told reporters that the new results belong to the two new drugs (improved new drugs), every two weeks intramuscular injection, has a clear clinical advantage. Its stable concentration of blood drugs in the body can avoid the risk of oral administration or overuse, can significantly improve oral antipsychotic drugs in patients with schizophrenia prevalence of drug compliance. In addition, after the suspension of the drug, the concentration of the drug in the body is significantly shorter than another commercially available drug, which is the doctor at any time to adjust the dose, which is currently on the market for long-acting antipsychotic drugs do not have the characteristics.
is understood to have entered the application phase for new drugs in the United States and is conducting key clinical studies in Europe. Previously, patents for this achievement were granted in China, the United States, Europe, Japan, South Korea, Russia, Canada and Australia, with a patent term of 2032.